Repligen to Report Second Quarter 2020 Financial Results
July 15 2020 - 7:30AM
Repligen Corporation (NASDAQ:RGEN) today announced that the Company
will report its second quarter 2020 financial results on Thursday,
July 30, 2020. The Company will issue a press release before the
market opens and will host a conference call at 8:30 a.m. EDT to
discuss business updates and financial results for the three- and
six- month reporting periods ended June 30, 2020.
The conference call will be accessible by dialing toll-free
(844) 701-1063 for domestic callers and (412) 317-5487 for
international callers. No passcode is required for the live call.
In addition, a webcast will be accessible via the Investor
Relations section of the Company’s website. Both the conference
call and webcast will be archived for a period of time following
the live event. The replay dial-in numbers are (877) 344-7529 for
callers in the U.S., (855) 669-9658 for callers in Canada and (412)
317-0088 for international callers. Replay listeners must provide
the passcode 10146361. About Repligen
CorporationRepligen Corporation is a global life sciences
company that develops and commercializes highly innovative
bioprocessing technologies and systems that increase efficiencies
in the process of manufacturing biological drugs. We are inspiring
advances in bioprocessing for the customers we serve; primarily
biopharmaceutical drug developers and contract development and
manufacturing organizations (CDMO’s) worldwide. Our corporate
headquarters are located in Waltham, MA (USA), and we have
additional administrative and manufacturing operations in
Marlborough, MA; Bridgewater, NJ; Rancho Dominguez, CA; Lund,
Sweden; Breda, The Netherlands and Ravensburg, Germany. This press
release may contain forward-looking statements within the meaning
of the federal securities laws. Investors are cautioned that
statements in this press release which are not strictly historical
statements including, without limitation, statements identified by
words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or
“could” and similar expressions, constitute forward-looking
statements. Such forward-looking statements are subject to a number
of risks and uncertainties that could cause actual results to
differ materially from those anticipated, including risks discussed
from time to time in our filings with the Securities and Exchange
Commission. We expressly disclaim any responsibility to update any
forward-looking statements, except as required by law.
Repligen Contact: Sondra S. NewmanGlobal
Head of Investor Relations(781)
419-1881investors@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024